Charles Schwab’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Charles Schwab’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-40,827	Closed	-$256K	–	3696
2022 Q1	$256K	Hold	40,827	–	–	﹤0.01%	3263
2021 Q4	$455K	Hold	40,827	–	–	﹤0.01%	3180
2021 Q3	$667K	Buy	40,827 +4,181	+11%	+$74.8K	﹤0.01%	3042
2021 Q2	$680K	Buy	36,646 +19,566	+115%	+$376K	﹤0.01%	3065
2021 Q1	$258K	Buy	17,080 +5,479	+47%	+$119K	﹤0.01%	3282
2020 Q4	$375K	Buy	+11,601	New	+$153K	﹤0.01%	3082

Other funds holding CDAK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Charles Schwab's CDAK Position: Q2 2022 in Review

Charles Schwab sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2022, closing a stake of 40,827 shares — an estimated $256K sold.

Charles Schwab first reported a position in CDAK in Q4 2020 and held it in 6 quarters. The position peaked at $680K in Q2 2021. 49 funds tracked by Wall St. Rank hold CDAK as of Q2 2022.

Charles Schwab reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Charles Schwab sold 40,827 Codiak BioSciences, Inc. Common Stock shares in Q2 2022, an estimated $256K.
Charles Schwab first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Charles Schwab's Codiak BioSciences, Inc. Common Stock position peaked at $680K in Q2 2021.
49 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.